Jaguar Health (JAGX) Operating Income (2014 - 2026)
Jaguar Health (JAGX) posted quarterly Operating Income of $10.2 million for Q1 2026, up 208.08% year-over-year from $3.3 million in Q1 2025, and up 147.93% quarter-over-quarter from -$21.2 million in Q4 2025.
Jaguar Health (JAGX) Operating Income (2014 - 2026) Analysis & Trends
Jaguar Health (JAGX) has reported Operating Income for 13 consecutive years, with $10.2 million the latest figure, recorded in Q1 2026.
- In Q1 2026, Operating Income rose 208.08% year-over-year to $10.2 million; the TTM figure through Mar 2026 stood at -$26.3 million (up 17.89% YoY), while the FY2025 annual figure was -$45.9 million, down 48.9% from the prior year.
- Operating Income advanced to $10.2 million in Q1 2026 per JAGX's latest filing, from -$21.2 million in the prior quarter.
- Across five years, Operating Income topped out at $10.2 million in Q1 2026 and bottomed at -$21.2 million in Q4 2025.
- Historically, Operating Income has averaged -$8.0 million across 5 years, with a median of -$8.1 million in 2023.
- Annual changes were most pronounced in 2025 — Operating Income plunged 160.41% — and 2026, when it soared 208.08%.
- Jaguar Health's Operating Income stood at -$6.3 million in 2022, then dropped by 20.22% to -$7.6 million in 2023, then retreated by 7.94% to -$8.2 million in 2024, then plunged by 160.41% to -$21.2 million in 2025, then soared by 147.93% to $10.2 million in 2026.
- Business Quant data shows JAGX's Operating Income at $10.2 million in Q1 2026, -$21.2 million in Q4 2025, and -$7.2 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Op. Inc (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.64 Bn | 130.78 Bn | 2.84 Bn | 1.25 Bn |
| 2 | Regeneron Pharmaceuticals | 85.89 Bn | 77.90 Bn | 3.93 Bn | 1.29 Bn |
| 3 | Argenx Se | 65.11 Bn | 59.93 Bn | 1.37 Bn | 493.00 Mn |
| 4 | Moderna | 55.83 Bn | 50.69 Bn | 52.00 Mn | -815.00 Mn |
| 5 | BeOne Medicines | 42.01 Bn | 36.91 Bn | 1.53 Bn | 325.05 Mn |
| 6 | Alnylam Pharmaceuticals | 31.63 Bn | 28.32 Bn | 992.69 Mn | 231.44 Mn |
| 7 | BioNTech SE | 27.65 Bn | 9.26 Bn | 668.28 Mn | -375.75 Mn |
| 8 | Insmed | 27.46 Bn | 26.30 Bn | 358.27 Mn | -1.55 Mn |
| 9 | Royalty Pharma | 27.30 Bn | 26.47 Bn | - | 133.12 Mn |
| 10 | Jaguar Health | 446,827.14 | -9.62 Mn | 19.11 Mn | 10.18 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 10.18 Mn |
| Dec 31, 2025 | -21.24 Mn |
| Sep 30, 2025 | -7.24 Mn |
| Jun 30, 2025 | -8.01 Mn |
| Mar 31, 2025 | -9.42 Mn |
| Dec 31, 2024 | -8.16 Mn |
| Sep 30, 2024 | -7.26 Mn |
| Jun 30, 2024 | -7.20 Mn |
| Mar 31, 2024 | -8.22 Mn |
| Dec 31, 2023 | -7.56 Mn |
| Sep 30, 2023 | -8.79 Mn |
| Jun 30, 2023 | -8.10 Mn |
| Mar 31, 2023 | -9.85 Mn |
| Dec 31, 2022 | -6.29 Mn |
| Sep 30, 2022 | -9.90 Mn |
| Jun 30, 2022 | -6.48 Mn |
| Mar 31, 2022 | -11.75 Mn |
| Dec 31, 2021 | -10.82 Mn |
| Sep 30, 2021 | -9.53 Mn |
| Jun 30, 2021 | -11.58 Mn |